Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
about
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trialsBiological activity of lenalidomide and its underlying therapeutic effects in multiple myelomaMultiple myelomaElotuzumab for the treatment of multiple myelomaSalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Chemotherapy-induced peripheral neuropathy: an update on the current understandingTreatment of relapsed and refractory multiple myelomaMonoclonal antibodies targeting CD38 in hematological malignancies and beyondEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Novel agents for multiple myeloma to overcome resistance in phase III clinical trialsEvidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myelomaCurrent and emerging treatment options for patients with relapsed myelomaFrom clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaUse of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in KoreaMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)New criteria for response assessment: role of minimal residual disease in multiple myelomaThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveRecent advances in multiple myeloma: a Korean perspectiveCost-effectiveness of bortezomib for multiple myeloma: a systematic reviewSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateSmall compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myelomaTargeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivoPhase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancerCombination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitorsMulti-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and OsteoblastsTriplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialReview of health-related quality of life data in multiple myeloma patients treated with novel agents."Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data.Treatment of multiple myeloma bone disease: experimental and clinical data.Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.Pomalidomide is active in the treatment of anemia associated with myelofibrosis
P2860
Q21133524-7B0A00C4-DF68-4C0A-A10A-F406D6E9DA14Q21285161-EE1E9DD0-4CF6-483B-9BA3-2B45A734E1E7Q24655964-422B7A16-BB78-49E0-831F-1DCD0D37FCD6Q26740278-97D6F8D5-392E-4DD8-B169-E9ABB2DD3081Q26740359-E1DD2262-9C11-4C16-85A9-9AB8267FD4E3Q26740689-5510C09E-FEAD-4291-84FD-D608E2C5D272Q26749180-ABF3DE18-14D7-4C00-8BB3-C512780FC056Q26766718-2AF010F1-5002-431C-BDA4-9B63259E32F0Q26771331-75402435-F7C7-453E-86D1-BEA90795816FQ26782868-1D349F4E-6AC8-41DA-BE6A-A0B3EB5FC54EQ26785497-2B42FF6F-0ACB-43B7-834F-BF481EAB4B3FQ26822754-CAF9475F-057E-4733-A8A5-79DCDC8E6085Q26823292-B27C26B0-0A51-4F50-BE3A-2E1705299191Q26830878-1807F577-5615-485D-8EF1-CA8063A3E506Q26862828-E0530DFA-B021-4E9C-8311-E0F8032E7545Q26992002-3739F1F2-C3E7-45E3-8015-7503D5C09753Q26998884-84A30714-2DE2-4B6B-9871-04B8F84033F8Q27002668-AFEA9925-49A9-498C-A332-793029C36E6FQ27004421-BB94D89D-C2DC-4B21-A960-D58813BCBD6DQ27027512-5243F89C-B0AD-4FEE-B86A-CCDD0F4141E1Q28069789-23F33214-3C81-4B65-8A82-F1D247E7A806Q28074521-3BF8B0DA-4443-4C3D-86A7-140A1B3129FEQ28075297-F4260FB5-DB8B-4B3B-8A98-1D662FF49298Q28076147-4EC4CEAF-9379-4EAB-AF19-BB3CDC4A1679Q28478936-62DD4C1E-1690-491E-9010-413B9AFDBCAFQ28483760-D657663B-0CE4-4D40-B4BF-DF59043672F0Q28534997-0277C676-D18B-4A6C-8D7E-8A2905611B6CQ28537997-24410AEC-D7CC-4504-9C2B-EC892EB12D50Q28551480-47CA76FE-C66C-4B55-9EF4-442259C154AEQ30238893-6955B28A-515E-4AA7-8484-590052BD76CFQ30249513-4D56F766-F715-41A0-AE58-A844D2F475AFQ30275870-08049139-8733-4B71-8DF4-D681B0647DB2Q30358639-14F85A28-0644-4CED-9387-D8C845A0ACF2Q30433139-C37B9441-DC2B-4875-97C7-839D47625DDBQ30650394-DE5A1A2E-D6B2-46D5-8A4B-5C6498CC7601Q30657752-38A84B8E-0B5F-4F47-A516-03904CF8873BQ30669943-CCD9BAD3-97F3-40DE-93A0-BE4148ADC608Q30868833-CFAA968A-CEAE-4CB6-A9D5-6CDF21DCD73CQ33385308-078FCF56-CA1A-4FB4-A813-CE9D422E3CF2Q33385644-E62AEE9C-0538-4087-981E-ED70316CFC01
P2860
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
@ast
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
@en
type
label
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
@ast
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
@en
prefLabel
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
@ast
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
@en
P2093
P50
P356
P1476
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
@en
P2093
Alessandro Corso
Andrew Spencer
Andrzej Hellmann
H Miles Prince
Jean-Luc Harousseau
Jerome B Zeldis
John Patin
Marta Olesnyckyj
Michael Attal
Multiple Myeloma (010) Study Investigators
P304
P356
10.1056/NEJMOA070594
P407
P577
2007-11-01T00:00:00Z